Literature DB >> 15456259

Modeling the protonation states of the catalytic aspartates in beta-secretase.

Ramkumar Rajamani1, Charles H Reynolds.   

Abstract

Beta-secretase (BACE) is a critical enzyme in the production of beta-amyloid, a protein that has been implicated as a potential cause of Alzheimer's disease (AD). There are two aspartic acid residues (Asp 32 and Asp 228) present in the catalytic region of BACE that can adopt multiple protonation states. The protonation state and precise location of the protons for these two residues, particularly in the presence of an inhibitor, are subjects of great interest since they have a direct bearing on the mechanism of aspartyl proteases and efforts to model beta-secretase. We have carried out full liner-scaling quantum mechanical (QM) calculations that include Poisson-Boltzmann solvation in order to identify the preferred protonation state and proton location in the presence and absence of an inhibitor. These calculations favor the monoprotonated state in the presence of ligand, and di-deprotonated state in the absence of ligand. Further the proton in the monoprotonated state is located on the inner oxygen of Asp 228. These results have implications for the catalytic mechanism of BACE and related aspartyl proteases. They also provide a reference state for the protein in structure-based modeling studies of this therapeutically important target.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15456259     DOI: 10.1021/jm049817j

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  9 in total

1.  Determination of the protonation state of the Asp dyad: conventional molecular dynamics versus thermodynamic integration.

Authors:  Jinfeng Huang; Yali Zhu; Bin Sun; Yuan Yao; Junjun Liu
Journal:  J Mol Model       Date:  2016-02-17       Impact factor: 1.810

2.  Quantum mechanics study of the hydroxyethylamines-BACE-1 active site interaction energies.

Authors:  Carlos Gueto-Tettay; Juan Carlos Drosos; Ricardo Vivas-Reyes
Journal:  J Comput Aided Mol Des       Date:  2011-06-21       Impact factor: 3.686

3.  Assigning the protonation states of the key aspartates in β-Secretase using QM/MM X-ray structure refinement.

Authors:  Ning Yu; Seth A Hayik; Bing Wang; Ning Liao; Charles H Reynolds; Kenneth M Merz
Journal:  J Chem Theory Comput       Date:  2006       Impact factor: 6.006

4.  Molecular modeling, synthesis, and activity studies of novel biaryl and fused-ring BACE1 inhibitors.

Authors:  Srinivas Reddy Chirapu; Boobalan Pachaiyappan; Hikmet F Nural; Xin Cheng; Hongbin Yuan; David C Lankin; Samer O Abdul-Hay; Gregory R J Thatcher; Yong Shen; Alan P Kozikowski; Pavel A Petukhov
Journal:  Bioorg Med Chem Lett       Date:  2008-10-25       Impact factor: 2.823

5.  Retrospective molecular docking study of WY-25105 ligand to β-secretase and bias of the three-dimensional structure flexibility.

Authors:  Leo Ghemtio; Nicolas Muzet
Journal:  J Mol Model       Date:  2013-04-07       Impact factor: 1.810

6.  Exploring the binding of BACE-1 inhibitors using comparative binding energy analysis (COMBINE).

Authors:  Shu Liu; Rao Fu; Xiao Cheng; Sheng-Ping Chen; Li-Hua Zhou
Journal:  BMC Struct Biol       Date:  2012-08-27

Review 7.  Computational Insights into Substrate and Site Specificities, Catalytic Mechanism, and Protonation States of the Catalytic Asp Dyad of β -Secretase.

Authors:  Arghya Barman; Rajeev Prabhakar
Journal:  Scientifica (Cairo)       Date:  2014-09-18

8.  Conformational Dynamics and Binding Free Energies of Inhibitors of BACE-1: From the Perspective of Protonation Equilibria.

Authors:  M Olivia Kim; Patrick G Blachly; J Andrew McCammon
Journal:  PLoS Comput Biol       Date:  2015-10-27       Impact factor: 4.475

9.  Changing Paradigm from one Target one Ligand Towards Multi-target Directed Ligand Design for Key Drug Targets of Alzheimer Disease: An Important Role of In Silico Methods in Multi-target Directed Ligands Design.

Authors:  Akhil Kumar; Ashish Tiwari; Ashok Sharma
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.